Cediranib Combined with Olaparib in Patients with Platinum-Pretreated SCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Patients with platinum-pretreated SCLC may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor.

Olaparib (Lynparza), a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated clinical efficacy in patients with various types of advanced solid tumors who carry a germline BRCA mutation.1 Researchers explored the antitumor activity of cediranib (Recentin), an oral vascular endothelial growth factor (VEGF) receptor inhibitor, combined with olaparib, a PARP inhibitor, in patients with advanced solid tumors, including patients with SCLC.2

This phase 2, multicenter, 2-stage study enrolled patients with metastatic SCLC who were previously treated in the advanced setting with ≥1 platinum-based chemotherapy regimens. Patients received cediranib 30 mg by mouth once daily plus olaparib 200 mg by mouth twice daily until disease progression or unacceptable toxicity. The study’s primary end point was ORR by RECIST version 1.1. Baseline tumor biopsies were obtained to perform biomarker analyses.2

A total of 25 patients were enrolled in this study, with a median age of 67 years (range, 46-79 years) and a median number of previous therapies of 2 (range, 1-5).2 Most (80%) were platinum-sensitive, and half (52%) had been treated with immunotherapy.2

Among these patients, the ORR associated with cediranib plus olaparib was 28% (95% CI, 10%-46%).2 Among responders, the median DOR was 3.8 months; 6 of 8 responding patients had an objective response that lasted more than 3 months and up to 10.3 months.2 The rate of disease control (complete response plus partial response plus stable disease) was 88% (95% CI, 75%-100%).2 Median PFS was 4.1 months (95% CI, 2.3-6.2 months).2 Median OS was 5.5 months (95% CI, 3.4-not available).2

Grade 3/4 AEs, irrespective of attribution, were observed in 12 of 25 patients (48%).2 Grade 3/4 AEs that occurred in more than 10% of patients were hypertension (21%), fatigue (17%), and weight loss (13%).2

Researchers concluded that the combination of cediranib plus olaparib resulted in promising clinical activity in patients with platinum-pretreated SCLC, with an ORR of 28% in biomarker-unselected patients.2 In some patients, this regimen required prompt initiation of antihypertensives. AEs were manageable overall.2 Analyses of mutation status in homologous recombination DNA repair genes are ongoing to learn whether mutational status correlates with clinical activity.2

References
1. Caulfield SE, Davis CC, Byers KF. Olaparib: a novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation. J Adv Pract Oncol. 2019;10:167-174.
2. Kim JW, Hafez N, Soliman HH, et al. Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: a phase II study of cediranib in combination with olaparib in advanced solid tumors. J Clin Oncol. 2020;38(15_suppl). Abstract 9065.

Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: